-
-
-
-
-
-
-
Roth/MKM Starts Arcturus Therapeutics (ARCT) at Buy
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) PT Lowered to $68 at Laidlaw
-
-
-
-
-
-
-
Scotiabank Starts Arcturus Therapeutics (ARCT) at Sector Outperform
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) PT Lowered to $45 at Guggenheim
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Receives FDA “Study May Proceed” Notice for ARCT-032
-
430,616 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

